Bridge Neurotech emerges from stealth with ultrasound brain interface

Bridge Neurotech announced on October 6 that it is emerging from stealth with a fully non-invasive ultrasound brain-computer interface, positioning itself as a challenger to surgical implant approaches. The company also revealed a partnership with Butterfly Network, licensing the company's Ultrasound-on-Chip technology to read brain activity without surgery or implants, and said it has opened its first human research study enrolling participants in Redwood City, California.

The Butterfly deal includes payments to Butterfly Network alongside a multi-year hardware purchase commitment, giving Bridge Neurotech a manufacturing and supply foundation as it moves from stealth into human research. Ultrasound-based interfaces work by sending high-frequency sound waves into the brain and interpreting the echoes — a fundamentally different path from electrodes implanted in neural tissue.

The Butterfly Network partnership

Licensing Butterfly's Ultrasound-on-Chip technology gives the startup access to miniaturized ultrasound hardware originally developed for medical imaging. The bet is that the same chip-scale engineering that put ultrasound probes in clinicians' pockets can be adapted to listen to the brain through the skull — no incisions, no implanted electronics, no neurosurgery.

The multi-year hardware purchase commitment suggests Bridge Neurotech expects to need significant device volume as its research program scales. For Butterfly, the arrangement converts its chip platform into a recurring revenue relationship with a company chasing one of the most ambitious applications in neurotechnology.

Non-invasive brain interfaces have been pursued for decades, but most have traded safety for signal quality — reading the brain from outside the skull has historically meant coarse, noisy data. Ultrasound is attracting fresh attention because it offers a middle path: better spatial resolution than scalp electrodes, without the risks of opening the skull.

A founder with two loyalties

The announcement carries an unusual twist: Bridge Neurotech founder and CEO Will Biederman is also the co-founder and chief technology officer of Forest Neurotech, the nonprofit that Sam Altman's Merge Labs spun out. Merge Labs itself emerged in January with a $252 million seed round at an $850 million valuation, led by OpenAI and joined by Bain Capital, Interface Fund, Fifty Years and Gabe Newell.

Both organizations are chasing ultrasound brain-computer interfaces as a non-invasive alternative to Neuralink's surgical implants, which means Biederman now leads two separate efforts attacking the same problem from different institutional perches — one a venture-backed startup, the other a nonprofit born from one of the best-funded new labs in AI. That dual role is already one of the most talked-about details of the launch, as reported by Startup Fortune.

The overlap raises obvious questions about intellectual property, focus, and competitive dynamics — but it also underscores how small and interconnected the ultrasound BCI world remains. The field's talent pool is narrow, and its biggest bets are being placed by people who know each other well.

Backers and the road from lab to clinic

Bridge Neurotech's investor roster includes General Catalyst, reMind Capital, Sunflower Capital, Oxford Seed Fund, Position Ventures, TreeHub and Scott Sandell — a mix of institutional venture firms and angels willing to fund hardware-heavy neuroscience. The company's first human research study, now enrolling in Redwood City, will be the first real test of whether its non-invasive approach can produce usable neural signals in people.

Human studies are the chokepoint for every brain-computer interface company. Surgical approaches like Neuralink's have demonstrated striking capabilities but face inherent limits on who will — or should — undergo brain surgery for an interface. A genuinely effective non-invasive system could sidestep that bottleneck entirely, opening brain-computer interfaces to far larger populations.

The broader BCI funding landscape has been heating up on multiple fronts, from Sequoia China's leadership of a major brain-computer interface round for Tianfukang, as GenZ NewZ reported, to the steady advance of open-weight AI models like Reflection AI's upcoming release, also covered here, which could supply the decoding intelligence these interfaces need.

Why it matters

For readers, Bridge Neurotech's bet is simple: the brain-computer interface that changes lives may be the one nobody has to get surgery for. If ultrasound can read the brain reliably through the skull, assistive communication, prosthetic control and new forms of human-computer interaction could reach millions of people who would never consider an implant. The Redwood City study is the first step in finding out whether that promise survives contact with real human biology.